Overview BENEFIT Extension Study Status: Completed Trial end date: 2011-01-01 Target enrollment: Participant gender: Summary To assess the long-term effects of early therapeutic intervention, i.e. within two years following a first clinical demyelinating event suggestive of MS. Details Lead Sponsor: BayerTreatments: Interferon beta-1bInterferon-betaInterferons